These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10697753)

  • 41. Mechanistic evaluation of the effect of sintering on Compritol 888 ATO matrices.
    Rao M; Ranpise A; Borate S; Thanki K
    AAPS PharmSciTech; 2009; 10(2):355-60. PubMed ID: 19333763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation and In Vitro and In Vivo Evaluation of Lipid-Based Terbutaline Sulphate Bi-layer Tablets for Once-Daily Administration.
    Hashem FM; Nasr M; Fathy G; Ismail A
    AAPS PharmSciTech; 2016 Jun; 17(3):727-34. PubMed ID: 26335420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals.
    Aburahma MH; Badr-Eldin SM
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1865-83. PubMed ID: 25152197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z; Schwartz JB; Sugita ET
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intersubject variability of serum theophylline concentration after single dose of uncoated controlled release theophylline tablet administration in asthmatic patients.
    Raj NS; Guleria R; Misra A; Pande JN
    Indian J Chest Dis Allied Sci; 1997; 39(3):143-7. PubMed ID: 9357147
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media.
    Fassihi AR; Munday DL
    J Pharm Pharmacol; 1989 Jun; 41(6):369-72. PubMed ID: 2570830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physicochemical characterization and mechanisms of release of theophylline from melt-extruded dosage forms based on a methacrylic acid copolymer.
    Young CR; Dietzsch C; Cerea M; Farrell T; Fegely KA; Rajabi-Siahboomi A; McGinity JW
    Int J Pharm; 2005 Sep; 301(1-2):112-20. PubMed ID: 16055285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro controlled release of colon targeted mesalamine from compritol ATO 888 based matrix tablets using factorial design.
    Patel JK; Patel NV; Shah SH
    Res Pharm Sci; 2009 Jul; 4(2):63-75. PubMed ID: 21589801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronopharmacokinetics of theophylline administered as a controlled-release tablet.
    Thielemann AM; Manquez N; Pinilla E; Gai MN; Romero P; Arancibia A; Chavez H
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):130-3. PubMed ID: 8705090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction.
    Jannin V; Rosiaux Y; Doucet J
    J Control Release; 2015 Jan; 197():158-64. PubMed ID: 25445699
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and optimization of colon-targeted system of theophylline for chronotherapy of nocturnal asthma.
    Patel MM; Amin AF
    J Pharm Sci; 2011 May; 100(5):1760-72. PubMed ID: 21154966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlled-release carbamazepine granules and tablets comprising lipophilic and hydrophilic matrix components.
    Barakat NS; Elbagory IM; Almurshedi AS
    AAPS PharmSciTech; 2008; 9(4):1054-62. PubMed ID: 18843537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dry adsorbed emulsion: 2. Dissolution behaviour of an intricate formulation.
    Chambin O; Bérard V; Rochat-Gonthier MH; Pourcelot Y
    Int J Pharm; 2002 Mar; 235(1-2):169-78. PubMed ID: 11879752
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies of chitosan/Kollicoat SR 30D film-coated tablets for colonic drug delivery.
    Fan LF; He W; Chang YZ; Xiang B; Du Q; Wang F; Qin M; Cao DY
    Int J Pharm; 2009 Jun; 375(1-2):8-15. PubMed ID: 19457627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets.
    Shah VP; Yamamoto LA; Schuirman D; Elkins J; Skelly JP
    Pharm Res; 1987 Oct; 4(5):416-9. PubMed ID: 3508552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets.
    Meruva S; Rezaei L; Thool P; Donovan MD
    AAPS PharmSciTech; 2020 Oct; 21(7):270. PubMed ID: 33025237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of matrix-based theophylline sustained-release microtablets.
    Rey H; Wagner KG; Wehrlé P; Schmidt PC
    Drug Dev Ind Pharm; 2000 Jan; 26(1):21-6. PubMed ID: 10677806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug release in vitro--an aid in clinical trials?
    Voegele D
    Methods Find Exp Clin Pharmacol; 1999; 21(1):55-62. PubMed ID: 10222448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and evaluation of a controlled-release theophylline tablet. Preliminary communication.
    Gai MN; Pezoa R; Corbeaux J; Arancibia A
    Farmaco; 1989 Nov; 44(11):1119-26. PubMed ID: 2701966
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel method for the preparation of controlled-release theophylline granules coated with a polyelectrolyte complex of sodium polyphosphate-chitosan.
    Kawashima Y; Handa T; Kasai A; Takenaka H; Lin SY; Ando Y
    J Pharm Sci; 1985 Mar; 74(3):264-8. PubMed ID: 4009432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.